Skip to main content
Erschienen in: Diagnostic Pathology 1/2013

Open Access 01.12.2013 | Case Report

Unexpected development of tongue squamous cell carcinoma after sclerotherapy for the venous malformation: a unique case report and literature review

verfasst von: Gang Chen, Xu Cai, Jian-Gang Ren, Jun Jia, Yi-Fang Zhao

Erschienen in: Diagnostic Pathology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Sclerotherapy is a common and effective treatment for venous diseases, including venous malformations (VMs), which are common vascular anomalies in the oral and maxillofacial regions. However, the safety of sclerotherapy has not been fully elucidated. Occasionally, patients who underwent sclerotherapy may present diverse but minor side effects such as erythema, swelling, pain, tenderness, hyperpigmentation, skin ulceration and necrosis.

Case presentation

Here we report a unique case of a 65-year-old female patient presented with an original VM lesion on the right side of the tongue. Intralesional sclerotherapy and followed surgical resection resulted in major remission of the original lesion, without recurrence during a 3-year follow-up. However, two years later, the patient was again referred to us for a painful mass on the right side of the tongue that gradually enlarged for 1 month. The mass was biopsied under local anesthesia after complete systematic examination, and the result indicated a well-differentiated squamous cell carcinoma (SCC). Then, the patient underwent right neck dissection, extensive resection of the SCC, reconstruction of the defect with forearm flap, microvascular anastomosis, and repair of the forearm defect with free abdomen skin graft.

Conclusion

To the best of our knowledge, this is the first study to document the development of oral SCC after sclerotherapy for VM, underscoring the need for long-term follow-up.

Virtual slides

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Eifert S, Villavicencio JL, Kao TC, Taute BM, Rich NM: Prevalence of deep venous anomalies in congenital vascular malformations of venous predominance. J Vasc Surg. 2000, 31: 462-471.CrossRefPubMed Eifert S, Villavicencio JL, Kao TC, Taute BM, Rich NM: Prevalence of deep venous anomalies in congenital vascular malformations of venous predominance. J Vasc Surg. 2000, 31: 462-471.CrossRefPubMed
2.
Zurück zum Zitat Brouillard P, Vikkula M: Genetic causes of vascular malformations. Hum Mol Genet. 2007, 16: Spec No. 2:R140-9-CrossRef Brouillard P, Vikkula M: Genetic causes of vascular malformations. Hum Mol Genet. 2007, 16: Spec No. 2:R140-9-CrossRef
3.
Zurück zum Zitat Guillemot F, Bonnière P, Bretagne JF, Ancelin JP, Raoul JL, Plane C, Cortot A, Paris JC: Esophageal cancer and endoscopic sclerosis of esophageal varices: a fortuitous association [abstract]?. Gastroenterol Clin Biol. 1988, 12: 858-861.PubMed Guillemot F, Bonnière P, Bretagne JF, Ancelin JP, Raoul JL, Plane C, Cortot A, Paris JC: Esophageal cancer and endoscopic sclerosis of esophageal varices: a fortuitous association [abstract]?. Gastroenterol Clin Biol. 1988, 12: 858-861.PubMed
4.
Zurück zum Zitat Kokudo N, Sanjo K, Umekita N, Harihara Y, Tada Y, Idezuki Y: Squamous cell carcinoma after endoscopic injection sclerotherapy for esophageal varices [abstract]. Am J Gastroenterol. 1990, 85: 861-864.PubMed Kokudo N, Sanjo K, Umekita N, Harihara Y, Tada Y, Idezuki Y: Squamous cell carcinoma after endoscopic injection sclerotherapy for esophageal varices [abstract]. Am J Gastroenterol. 1990, 85: 861-864.PubMed
5.
Zurück zum Zitat Macias Rodriguez MA, de la Cruz MJ S, Iglesias Arrabal M, Martin Herrera L: Esophageal carcinoma after the endoscopic sclerotherapy of varices [abstract]. Span J Dig Dis. 1992, 82: 43-46. Macias Rodriguez MA, de la Cruz MJ S, Iglesias Arrabal M, Martin Herrera L: Esophageal carcinoma after the endoscopic sclerotherapy of varices [abstract]. Span J Dig Dis. 1992, 82: 43-46.
6.
Zurück zum Zitat Ohta M, Kuwano H, Hashizume M, Sonoda T, Tomikawa M, Higashi H, Ohno S, Watanabe M, Sugimachi K: Development of esophageal cancer after endoscopic injection sclerotherapy for esophageal varices: three case reports. Endoscopy. 1995, 27: 455-458. 10.1055/s-2007-1005742.CrossRefPubMed Ohta M, Kuwano H, Hashizume M, Sonoda T, Tomikawa M, Higashi H, Ohno S, Watanabe M, Sugimachi K: Development of esophageal cancer after endoscopic injection sclerotherapy for esophageal varices: three case reports. Endoscopy. 1995, 27: 455-458. 10.1055/s-2007-1005742.CrossRefPubMed
7.
Zurück zum Zitat Tanoue K, Hashizume M, Ohta M, Ueno K, Kitano S, Sugimachi K: Development of early squamous cell carcinoma of the esophagus after endoscopic injection sclerotherapy for esophageal varices [abstract]. Hepatogastroenterology. 1995, 42: 792-796.PubMed Tanoue K, Hashizume M, Ohta M, Ueno K, Kitano S, Sugimachi K: Development of early squamous cell carcinoma of the esophagus after endoscopic injection sclerotherapy for esophageal varices [abstract]. Hepatogastroenterology. 1995, 42: 792-796.PubMed
8.
Zurück zum Zitat Ng KW, Tan SW, Chen YH, Chen HC, Wu CS, Liang CT, Jiang CF: Esophageal cancer after endoscopic injection sclerotherapy for esophageal varices [abstract]. Zhonghua Yi Xue Za Zhi (Taipei). 2001, 64: 299-304. Ng KW, Tan SW, Chen YH, Chen HC, Wu CS, Liang CT, Jiang CF: Esophageal cancer after endoscopic injection sclerotherapy for esophageal varices [abstract]. Zhonghua Yi Xue Za Zhi (Taipei). 2001, 64: 299-304.
9.
Zurück zum Zitat Hashimoto Y, Imai A, Tokui N, Sasaki A, Saitoh H, Koie T, Ohyama C: Unexpected outcome after sclerotherapy of simple renal cyst. BMC Neurol. 2012, 13: 63-10.1186/1471-2202-13-63.CrossRef Hashimoto Y, Imai A, Tokui N, Sasaki A, Saitoh H, Koie T, Ohyama C: Unexpected outcome after sclerotherapy of simple renal cyst. BMC Neurol. 2012, 13: 63-10.1186/1471-2202-13-63.CrossRef
10.
Zurück zum Zitat Baek HJ, Hong JP, Choi JW, Suh DC: Direct percutaneous alcohol sclerotherapy for venous malformations of head and neck region without fluoroscopic guidance: technical consideration and outcome. Neurointervention. 2011, 6: 84-88. 10.5469/neuroint.2011.6.2.84.PubMedCentralCrossRefPubMed Baek HJ, Hong JP, Choi JW, Suh DC: Direct percutaneous alcohol sclerotherapy for venous malformations of head and neck region without fluoroscopic guidance: technical consideration and outcome. Neurointervention. 2011, 6: 84-88. 10.5469/neuroint.2011.6.2.84.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Zheng JW, Yang XJ, Wang YA, He Y, Ye WM, Zhang ZY: Intralesional injection of pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients. Oral oncology. 2009, 45: 872-876. 10.1016/j.oraloncology.2009.02.011.CrossRefPubMed Zheng JW, Yang XJ, Wang YA, He Y, Ye WM, Zhang ZY: Intralesional injection of pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients. Oral oncology. 2009, 45: 872-876. 10.1016/j.oraloncology.2009.02.011.CrossRefPubMed
12.
Zurück zum Zitat Zhao JH, Zhang WF, Zhao YF: Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate. Int J Oral Maxillofac Surg. 2004, 33: 463-466. 10.1016/j.ijom.2003.10.003.CrossRefPubMed Zhao JH, Zhang WF, Zhao YF: Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate. Int J Oral Maxillofac Surg. 2004, 33: 463-466. 10.1016/j.ijom.2003.10.003.CrossRefPubMed
13.
Zurück zum Zitat Hemmings C: Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis. Pathology. 2013, 45: 371-381. 10.1097/PAT.0b013e328360b600.CrossRefPubMed Hemmings C: Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis. Pathology. 2013, 45: 371-381. 10.1097/PAT.0b013e328360b600.CrossRefPubMed
14.
Zurück zum Zitat Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y: Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010, 43: 161-172. 10.1165/rcmb.2009-0031OC.PubMedCentralCrossRefPubMed Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y: Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010, 43: 161-172. 10.1165/rcmb.2009-0031OC.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Zhang W, Chen G, Ren JG, Zhao YF: Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol. 2013, doi:10.1111/bph.12355 [Epub ahead of print] Zhang W, Chen G, Ren JG, Zhao YF: Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol. 2013, doi:10.1111/bph.12355 [Epub ahead of print]
16.
Zurück zum Zitat Liu Y, Dong XL, Tian C, Liu HG: Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagn Pathol. 2012, 7: 34-10.1186/1746-1596-7-34.PubMedCentralCrossRefPubMed Liu Y, Dong XL, Tian C, Liu HG: Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagn Pathol. 2012, 7: 34-10.1186/1746-1596-7-34.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Li G, Jin T, Liang H, Tu Y, Zhang W, Gong L, Su Q, Gao G: Skewed X-chromosome inactivation in patients with esophageal carcinoma. Diagn Pathol. 2012, 8: 55-CrossRef Li G, Jin T, Liang H, Tu Y, Zhang W, Gong L, Su Q, Gao G: Skewed X-chromosome inactivation in patients with esophageal carcinoma. Diagn Pathol. 2012, 8: 55-CrossRef
18.
Zurück zum Zitat El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol. 2012, 7: 170-10.1186/1746-1596-7-170.PubMedCentralCrossRefPubMed El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol. 2012, 7: 170-10.1186/1746-1596-7-170.PubMedCentralCrossRefPubMed
Metadaten
Titel
Unexpected development of tongue squamous cell carcinoma after sclerotherapy for the venous malformation: a unique case report and literature review
verfasst von
Gang Chen
Xu Cai
Jian-Gang Ren
Jun Jia
Yi-Fang Zhao
Publikationsdatum
01.12.2013
Verlag
BioMed Central
Erschienen in
Diagnostic Pathology / Ausgabe 1/2013
Elektronische ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-182

Weitere Artikel der Ausgabe 1/2013

Diagnostic Pathology 1/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …